Torrent Pharmaceuticals has announced the launch of its generic Semaglutide brands, Sembolic and Semalix, in both oral and injectable formulations in India as of March 21, 2026. This move positions Torrent as the first Indian company to offer generic oral semaglutide. The injectable formulation is priced starting at Rs. 3,999 per month, aiming to provide affordable options for managing Type-2 diabetes and obesity.
Torrent Pharma Enters GLP-1 Therapy Segment with Semaglutide Launch
On Saturday, March 21, 2026, Torrent Pharmaceuticals Ltd. officially launched its generic brands of Semaglutide—Sembolic and Semalix—in the Indian market. The launch covers both oral and injectable formulations, significantly expanding the company’s portfolio in metabolic disorders, specifically Type-2 diabetes and obesity.
Torrent Pharmaceuticals claims the distinction of being the First company in India to launch generic oral semaglutide. The injectable formulation has been priced competitively, starting at Rs. 3,999 per month.
Strategic Importance and Executive Commentary
Amal Kelshikar, CEO – India Business, Torrent Pharma, highlighted the significance of this launch: “Our entry into the GLP-1 therapy segment reflects Torrent’s commitment to expanding treatment options available to healthcare professionals managing complex metabolic conditions at affordable prices.”
GLP-1 (glucagon-like peptide-1) receptor agonists are recognized for enhancing insulin secretion, reducing glucagon levels, promoting weight loss, and reducing cardiovascular risk in patients with Type 2 diabetes.
Torrent Pharmaceuticals Profile Snapshot
Torrent Pharma is the flagship company of the Torrent Group, reporting annual revenues exceeding Rs 11,500 crores. Following the JB Pharma acquisition, the company is now ranked 5th in the Indian Pharmaceuticals Market. It holds a strong position in therapeutic segments including Cardiovascular (CV), Gastro Intestinal (GI), and Central Nervous System (CNS).
The company maintains a specialty focus, with approximately ~76% of its revenues derived from chronic & sub-chronic therapies. Torrent possesses 8 manufacturing facilities globally, with 5 being USFDA approved, backed by an R&D infrastructure employing over 750+ scientists.
Source: BSE
